Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
|Articles|October 1, 2004
Another baby and another cutaneous lesion--and more on efficient recognition and management
In this installment, the author helps you distinguish among vascular malformations, hemangiomas, and less common vascular tumors of infancy and identify the lesions associated with congenital syphilis. The first part of this article appeared in the July 2004 issue.
Advertisement
Advertisement
Related to this article
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
At AAP 2026, Peter Lio, MD, discussed distinguishing allergic and inflammatory skin conditions and when pediatricians should seek specialty care.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Youth-onset type 2 diabetes may progress faster, signs easy to miss
2
Hand, foot, and mouth disease: Red flags pediatricians should know
3
FDA grants Cinainu Breakthrough Therapy status for pediatric AA
4
FDA approval of Gazyva offers new option for pediatric INS
5